Global Cystic Fibrosis Therapeutics Market to Reach US$ 14.7 Billion by 2032, Propelled by the Increasing Number of Individuals Diagnosed with Cystic Fibrosis

April 21, 2023 | Healthcare

The latest report by IMARC, titled “Cystic Fibrosis Therapeutics Market Report by Drug Class (Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, CFTR Modulators, Antibiotics, and Others), Drug Molecule Type (Small Molecule Drugs, Biologics), Route of Administration (Oral Drugs, Inhaled Drugs), End-User (Hospitals, Clinics, and Others), and Region 2024-2032”, finds that the global cystic fibrosis therapeutics market size reached US$ 7.2 Billion in 2023. Cystic fibrosis therapeutics refers to the range of medical treatments and therapies used to manage the symptoms and complications of Cystic Fibrosis, which is a genetic disorder that affects various organs in the body, primarily the lungs and digestive system. Cystic fibrosis (CF) is caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which leads to the production of thick, sticky mucus in the lungs, pancreas, and other organs. The build-up of mucus can cause chronic lung infections, breathing difficulties, and digestive problems, among other complications. CF therapeutics may include medications such as antibiotics to prevent or treat infections, bronchodilators to open the airways, and mucolytics to help loosen and clear the thick mucus. Other therapies may include physical therapy and exercise to help clear mucus from the lungs, airway clearance techniques, and oxygen therapy. In recent years, cystic fibrosis therapeutics have gained traction as they help in improving lung function and reducing the frequency of pulmonary exacerbations, thus enhancing the overall quality of life for people with CF.

Global Cystic Fibrosis Therapeutics Market Trends:

One of the primary factors driving the market is the increasing number of individuals diagnosed with cystic fibrosis. Additionally, the increasing healthcare expenditure globally, on account of the rising aging population, increasing chronic disease burden and growing access to healthcare services, is creating a positive market outlook. Other than this, the rapid development of CFTR modulator therapies, such as ivacaftor, lumacaftor/ivacaftor, and tezacaftor/ivacaftor is vastly improving the treatment outcomes for patients, thus positively influencing the market growth. Besides this, various regulatory bodies, such as the United States Food and Drug Administration (USFDA) and the European Medicines Agency (EMA), are streamlining the approval procedures for CF therapeutics, thus making it easier for pharmaceutical companies to introduce new drugs into the market. In line with this, extensive investments in research and development (R&D) of new CT therapeutics, including gene therapies and next-generation CTFR modulators, are propelling the market growth. Looking forward, IMARC Group expects the market value to reach US$ 14.7 Billion by 2032, expanding at a CAGR of 7.9% during the forecast period (2024-2032).

Market Summary:

  • On the basis of the drug class, the market has been divided into pancreatic enzyme supplements, mucolytics, bronchodilators, CFTR modulators, antibiotics, and others.
  • Based on the drug molecule type, the market has been segmented into small molecule drugs and biologics.
  • On the basis of the route of administration, the market has been bifurcated into oral and inhaled drugs.
  • Based on the end user, the market has been categorized into hospitals, clinics, and others.
  • Region-wise, the market has been classified into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom. Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
  • The competitive landscape of the market has also been analyzed, with some of the key players being AbbVie Inc., Alaxia, Alcresta Therapeutics Inc., Allergan, AstraZeneca, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Merck & Co. Inc., Novartis AG, Teva Pharmaceutical Industries Ltd. and Vertex Pharmaceuticals Inc.

Report Coverage:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Segment Coverage Drug Class, Drug Molecule Type, Route of Administration, End-User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered AbbVie Inc., Alaxia, Alcresta Therapeutics Inc., Allergan, AstraZeneca, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Merck & Co. Inc., Novartis AG, Teva Pharmaceutical Industries Ltd. and Vertex Pharmaceuticals Inc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Cystic Fibrosis Therapeutics Market to Reach US$ 14.7 Billion by 2032, Propelled by the Increasing Number of Individuals Diagnosed with Cystic Fibrosis
Purchase options

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-714-6104


Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More